Female sexual arousal disorder

Sep 04, 2019

FDA Removes Alcohol Ban with Addyi - the First-and-Only Non-Hormonal Treatment for Hypoactive (Low) Sexual Desire Disorder (HSDD)

Jun 21, 2019

FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women

Jun 21, 2019

FDA Approves New Drug Application for Vyleesi(TM) (bremelanotide injection)

Jan 04, 2019

S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys(TM) for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting

Jun 27, 2018

Pivot Pharma To File Investigational New Drug (IND) Application With U.S. FDA For PVT-005

Mar 26, 2018

Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

Mar 12, 2018

Orbis Biosciences and Daré Bioscience Collaborate to Advance Innovation for Women's Reproductive Health

Aug 28, 2017

Developments in the Erectile Dysfunction Markets